In February 2022, the US District Court for the Eastern District of California held that California Assembly Bill 824—which established a first-of-its kind presumption that certain pharmaceutical patent settlements are...more
Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number...more
On April 4, 2020, the Antitrust Division of the Department of Justice issued its first Business Review Letter under the DOJ-FTC joint expedited COVID-19 competitor collaboration review procedures, blessing several medical...more
4/23/2020
/ Absolute Immunity ,
Antitrust Division ,
Antitrust Provisions ,
Business Review Letters ,
Collaboration ,
Competition ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
Federal Trade Commission (FTC) ,
Medical Devices ,
Medical Research ,
Medical Supplies ,
No-Action Letters ,
Personal Protective Equipment ,
Pharmaceutical Industry ,
Prescription Drugs